[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fRsuruRahb7Gm0eQw-RFhknGa159jd5GFxajAK4oGEVI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":8,"topConditions":11,"upcomingReadouts":32,"phaseBuckets":33,"rows":40},"Torrent Pharmaceuticals Limited",[4],72,false,0,3,3060,[12,15,18,21,24,26,28,30],{"name":13,"count":14},"Healthy",52,{"name":16,"count":17},"Healthy Subjects",11,{"name":19,"count":20},"Type 2 Diabetes",4,{"name":22,"count":23},"Diabetes",1,{"name":25,"count":23},"Dyslipidemias",{"name":27,"count":23},"Hypertension",{"name":29,"count":23},"Metabolic Cardiovascular Syndrome",{"name":31,"count":23},"Acne Vulgaris",[],[34,35,36,37,38,39],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[41,78,104,122,147,186,224,258,280,313,340,367,394,422,449,476,503,530,558,591,622,649,676,703,737,770,792,821,843,871,903,930,957,987,1009,1036,1064,1082,1100,1122,1140,1161,1179,1197,1219,1237,1259,1277,1299,1317,1335,1355,1376,1394,1415],{"intervention":42,"totalTrials":43,"cells":44},"TRC150094",2,{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":61,"PHASE4":74,"NA":76},{"trials":46,"activeCount":8},[],{"trials":48,"activeCount":8},[],{"trials":50,"activeCount":8},[51],{"nctId":52,"briefTitle":53,"status":54,"phases":55,"primaryCompletion":56,"start":57,"enrollment":58,"conditions":59,"interventions":60},"NCT01408667","Hyperinsulinemic Euglycemic Clamp Protocol","COMPLETED",[35,36],"2012-03","2011-11",40,[29],[42],{"trials":62,"activeCount":8},[63],{"nctId":64,"briefTitle":65,"status":66,"phases":67,"primaryCompletion":68,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":73},"NCT03254446","Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension","UNKNOWN",[37],"2022-04","2022-08","2018-03-12",1250,[22,25,27],[42],{"trials":75,"activeCount":8},[],{"trials":77,"activeCount":8},[],{"intervention":79,"totalTrials":23,"cells":80},"Dapsone gel 7.5%",{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":100,"NA":102},{"trials":82,"activeCount":8},[],{"trials":84,"activeCount":8},[],{"trials":86,"activeCount":8},[],{"trials":88,"activeCount":8},[89],{"nctId":90,"briefTitle":91,"status":54,"phases":92,"primaryCompletion":93,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":98},"NCT04015375","Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris",[37],"2020-02-03","2020-02-22","2019-07-11",1150,[31],[79,99],"ACZONE®",{"trials":101,"activeCount":8},[],{"trials":103,"activeCount":8},[],{"intervention":99,"totalTrials":23,"cells":105},{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":112,"PHASE4":118,"NA":120},{"trials":107,"activeCount":8},[],{"trials":109,"activeCount":8},[],{"trials":111,"activeCount":8},[],{"trials":113,"activeCount":8},[114],{"nctId":90,"briefTitle":91,"status":54,"phases":115,"primaryCompletion":93,"completion":94,"start":95,"enrollment":96,"conditions":116,"interventions":117},[37],[31],[79,99],{"trials":119,"activeCount":8},[],{"trials":121,"activeCount":8},[],{"intervention":123,"totalTrials":23,"cells":124},"TRC041266",{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":143,"NA":145},{"trials":126,"activeCount":8},[],{"trials":128,"activeCount":8},[],{"trials":130,"activeCount":8},[],{"trials":132,"activeCount":8},[133],{"nctId":134,"briefTitle":135,"status":136,"phases":137,"primaryCompletion":138,"completion":138,"start":139,"enrollment":8,"conditions":140,"interventions":142},"NCT04507347","Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus","WITHDRAWN",[37],"2024-06","2021-06",[141],"Chronic Stable Heart Failure",[123],{"trials":144,"activeCount":8},[],{"trials":146,"activeCount":8},[],{"intervention":148,"totalTrials":20,"cells":149},"Metformin",{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":184},{"trials":151,"activeCount":8},[],{"trials":153,"activeCount":8},[154,160,166,172],{"nctId":155,"briefTitle":156,"status":54,"phases":157,"conditions":158,"interventions":159},"NCT01089166","Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition",[35],[19],[148],{"nctId":161,"briefTitle":162,"status":54,"phases":163,"conditions":164,"interventions":165},"NCT01089192","Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fasting Conditions.",[35],[19],[148],{"nctId":167,"briefTitle":168,"status":54,"phases":169,"conditions":170,"interventions":171},"NCT01089205","Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fed Conditions.",[35],[19],[148],{"nctId":173,"briefTitle":174,"status":54,"phases":175,"conditions":176,"interventions":177},"NCT01089179","Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions",[35],[19],[148],{"trials":179,"activeCount":8},[],{"trials":181,"activeCount":8},[],{"trials":183,"activeCount":8},[],{"trials":185,"activeCount":8},[],{"intervention":187,"totalTrials":9,"cells":188},"Torrent's Esomeprazole Magnesium DR Capsules 40 mg",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":222},{"trials":190,"activeCount":8},[],{"trials":192,"activeCount":8},[193,202,209],{"nctId":194,"briefTitle":195,"status":54,"phases":196,"primaryCompletion":197,"completion":197,"start":197,"enrollment":198,"conditions":199,"interventions":200},"NCT02680132","Bioequivalence Study of Torrent Pharmaceutical Ltd's Esomeprazole Magnesium Delayed Release Capsules",[35],"2011-05",56,[13],[201,187],"Nexium 40 mg DR Capsules of AstraZeneca LP, USA",{"nctId":203,"briefTitle":204,"status":54,"phases":205,"primaryCompletion":197,"completion":197,"start":197,"enrollment":206,"conditions":207,"interventions":208},"NCT02659683","Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Esomeprazole Magnesium DR Capsules Under Fasting Conditions",[35],54,[16],[201,187],{"nctId":210,"briefTitle":211,"status":54,"phases":212,"primaryCompletion":197,"completion":197,"start":197,"enrollment":198,"conditions":213,"interventions":214},"NCT02680119","BE of Torrent's Esomeprazole Mg DR Capsules",[35],[13],[215,187],"Nexium 40 mg DR Capsules of AstraZeneca LP, USA.",{"trials":217,"activeCount":8},[],{"trials":219,"activeCount":8},[],{"trials":221,"activeCount":8},[],{"trials":223,"activeCount":8},[],{"intervention":225,"totalTrials":9,"cells":226},"Torrent's Quetiapine Fumarate",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":256},{"trials":228,"activeCount":8},[],{"trials":230,"activeCount":8},[231,238,244],{"nctId":232,"briefTitle":233,"status":54,"phases":234,"conditions":235,"interventions":237},"NCT01634373","Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets",[35],[236],"Schizophrenia",[225],{"nctId":239,"briefTitle":240,"status":54,"phases":241,"conditions":242,"interventions":243},"NCT01634386","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fasting Conditions",[35],[13],[225],{"nctId":245,"briefTitle":246,"status":54,"phases":247,"conditions":248,"interventions":249},"NCT01634399","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fed Conditions",[35],[13],[225],{"trials":251,"activeCount":8},[],{"trials":253,"activeCount":8},[],{"trials":255,"activeCount":8},[],{"trials":257,"activeCount":8},[],{"intervention":201,"totalTrials":43,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":261,"activeCount":8},[],{"trials":263,"activeCount":8},[264,268],{"nctId":194,"briefTitle":195,"status":54,"phases":265,"primaryCompletion":197,"completion":197,"start":197,"enrollment":198,"conditions":266,"interventions":267},[35],[13],[201,187],{"nctId":203,"briefTitle":204,"status":54,"phases":269,"primaryCompletion":197,"completion":197,"start":197,"enrollment":206,"conditions":270,"interventions":271},[35],[16],[201,187],{"trials":273,"activeCount":8},[],{"trials":275,"activeCount":8},[],{"trials":277,"activeCount":8},[],{"trials":279,"activeCount":8},[],{"intervention":281,"totalTrials":43,"cells":282},"Topiramate",{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":305,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":284,"activeCount":8},[],{"trials":286,"activeCount":8},[287,297],{"nctId":288,"briefTitle":289,"status":54,"phases":290,"primaryCompletion":291,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":296},"NCT00939692","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions",[35],"2007-03","2007-04","2007-01",26,[13],[281],{"nctId":298,"briefTitle":299,"status":54,"phases":300,"enrollment":301,"conditions":302,"interventions":303},"NCT00939705","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions",[35],18,[13],[304],"topiramate",{"trials":306,"activeCount":8},[],{"trials":308,"activeCount":8},[],{"trials":310,"activeCount":8},[],{"trials":312,"activeCount":8},[],{"intervention":314,"totalTrials":43,"cells":315},"Torrent's Clopidogrel Tablets USP 75 mg",{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":317,"activeCount":8},[],{"trials":319,"activeCount":8},[320,326],{"nctId":321,"briefTitle":322,"status":54,"phases":323,"conditions":324,"interventions":325},"NCT01630642","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Clopidogrel Tablets Under Fasting Conditions",[35],[13],[314],{"nctId":327,"briefTitle":328,"status":54,"phases":329,"conditions":330,"interventions":331},"NCT01630915","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Clopidogrel Tablets Under Fed Condition",[35],[13],[314],{"trials":333,"activeCount":8},[],{"trials":335,"activeCount":8},[],{"trials":337,"activeCount":8},[],{"trials":339,"activeCount":8},[],{"intervention":341,"totalTrials":43,"cells":342},"Losartan Potassium",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":359,"PHASE3":361,"PHASE4":363,"NA":365},{"trials":344,"activeCount":8},[],{"trials":346,"activeCount":8},[347,353],{"nctId":348,"briefTitle":349,"status":54,"phases":350,"conditions":351,"interventions":352},"NCT01218698","Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition",[35],[13],[341],{"nctId":354,"briefTitle":355,"status":54,"phases":356,"conditions":357,"interventions":358},"NCT01218022","Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fasting Condition",[35],[13],[341],{"trials":360,"activeCount":8},[],{"trials":362,"activeCount":8},[],{"trials":364,"activeCount":8},[],{"trials":366,"activeCount":8},[],{"intervention":368,"totalTrials":43,"cells":369},"Losartan Potassium and Hydrochlorothiazide",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":371,"activeCount":8},[],{"trials":373,"activeCount":8},[374,380],{"nctId":375,"briefTitle":376,"status":54,"phases":377,"conditions":378,"interventions":379},"NCT01218724","Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg \u002F 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg \u002F 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions",[35],[13],[368],{"nctId":381,"briefTitle":382,"status":54,"phases":383,"conditions":384,"interventions":385},"NCT01218711","Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg \u002F 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg \u002F 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions.",[35],[13],[368],{"trials":387,"activeCount":8},[],{"trials":389,"activeCount":8},[],{"trials":391,"activeCount":8},[],{"trials":393,"activeCount":8},[],{"intervention":395,"totalTrials":43,"cells":396},"Escitalopram Oxalate",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":420},{"trials":398,"activeCount":8},[],{"trials":400,"activeCount":8},[401,408],{"nctId":402,"briefTitle":403,"status":54,"phases":404,"primaryCompletion":405,"conditions":406,"interventions":407},"NCT01996462","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fasting Condition",[35],"2008-05",[13],[395],{"nctId":409,"briefTitle":410,"status":54,"phases":411,"primaryCompletion":405,"conditions":412,"interventions":413},"NCT01996475","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fed Condition",[35],[13],[395],{"trials":415,"activeCount":8},[],{"trials":417,"activeCount":8},[],{"trials":419,"activeCount":8},[],{"trials":421,"activeCount":8},[],{"intervention":423,"totalTrials":43,"cells":424},"Citalopram Hydrobromide",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":441,"PHASE3":443,"PHASE4":445,"NA":447},{"trials":426,"activeCount":8},[],{"trials":428,"activeCount":8},[429,435],{"nctId":430,"briefTitle":431,"status":54,"phases":432,"conditions":433,"interventions":434},"NCT00940238","Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition",[35],[13],[423],{"nctId":436,"briefTitle":437,"status":54,"phases":438,"conditions":439,"interventions":440},"NCT00939835","Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition",[35],[13],[423],{"trials":442,"activeCount":8},[],{"trials":444,"activeCount":8},[],{"trials":446,"activeCount":8},[],{"trials":448,"activeCount":8},[],{"intervention":450,"totalTrials":43,"cells":451},"Torrent's Pantoprazole Sodium Delayed - Release",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":453,"activeCount":8},[],{"trials":455,"activeCount":8},[456,462],{"nctId":457,"briefTitle":458,"status":54,"phases":459,"conditions":460,"interventions":461},"NCT01418417","Bioequivalence Study of Torrent Pharmaceutical Limited's Pantoprazole Sodium 40 mg Delayed Release Tablets Under Fasting Conditions",[35],[13],[450],{"nctId":463,"briefTitle":464,"status":54,"phases":465,"conditions":466,"interventions":467},"NCT01418443","Bioequivalence Study of Torrent Pharmaceutical Limited's Pantoprazole Sodium 40 mg Delayed Release Tablets Under Fed Conditions",[35],[13],[450],{"trials":469,"activeCount":8},[],{"trials":471,"activeCount":8},[],{"trials":473,"activeCount":8},[],{"trials":475,"activeCount":8},[],{"intervention":477,"totalTrials":43,"cells":478},"Metformin HCl",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":480,"activeCount":8},[],{"trials":482,"activeCount":8},[483,489],{"nctId":484,"briefTitle":485,"status":54,"phases":486,"conditions":487,"interventions":488},"NCT00944177","Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects",[35],[13],[477],{"nctId":490,"briefTitle":491,"status":54,"phases":492,"conditions":493,"interventions":494},"NCT00944346","Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects",[35],[13],[477],{"trials":496,"activeCount":8},[],{"trials":498,"activeCount":8},[],{"trials":500,"activeCount":8},[],{"trials":502,"activeCount":8},[],{"intervention":504,"totalTrials":43,"cells":505},"Lamotrigine",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":507,"activeCount":8},[],{"trials":509,"activeCount":8},[510,516],{"nctId":511,"briefTitle":512,"status":54,"phases":513,"conditions":514,"interventions":515},"NCT00939614","Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited, India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.",[35],[13],[504],{"nctId":517,"briefTitle":518,"status":54,"phases":519,"conditions":520,"interventions":521},"NCT00939458","Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects, Under Fed Conditions",[35],[13],[504],{"trials":523,"activeCount":8},[],{"trials":525,"activeCount":8},[],{"trials":527,"activeCount":8},[],{"trials":529,"activeCount":8},[],{"intervention":531,"totalTrials":43,"cells":532},"Torrent's Montelukast Sodium Tablets 10 mg",{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":556},{"trials":534,"activeCount":8},[],{"trials":536,"activeCount":8},[537,544],{"nctId":538,"briefTitle":539,"status":54,"phases":540,"primaryCompletion":541,"conditions":542,"interventions":543},"NCT01928069","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fed Conditions",[35],"2009-12",[13],[531],{"nctId":545,"briefTitle":546,"status":54,"phases":547,"primaryCompletion":541,"conditions":548,"interventions":549},"NCT01928056","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fasted Conditions",[35],[13],[531],{"trials":551,"activeCount":8},[],{"trials":553,"activeCount":8},[],{"trials":555,"activeCount":8},[],{"trials":557,"activeCount":8},[],{"intervention":559,"totalTrials":43,"cells":560},"Torrent's Nebivolol",{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":562,"activeCount":8},[],{"trials":564,"activeCount":8},[565,575],{"nctId":566,"briefTitle":567,"status":54,"phases":568,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":573},"NCT03517020","Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet",[35],"2011-06","2011-04",22,[16],[559,574],"Forest Pharmaceuticals Inc's Bystolic",{"nctId":576,"briefTitle":577,"status":54,"phases":578,"primaryCompletion":569,"completion":569,"start":197,"enrollment":579,"conditions":580,"interventions":581},"NCT03517033","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet",[35],30,[16],[559,582],"Forest Pharmaceuticals Inc.'s Bystolic",{"trials":584,"activeCount":8},[],{"trials":586,"activeCount":8},[],{"trials":588,"activeCount":8},[],{"trials":590,"activeCount":8},[],{"intervention":592,"totalTrials":43,"cells":593},"Torrent's Fluoxetine",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":614,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":595,"activeCount":8},[],{"trials":597,"activeCount":8},[598,607],{"nctId":599,"briefTitle":600,"status":54,"phases":601,"primaryCompletion":602,"completion":602,"start":603,"enrollment":294,"conditions":604,"interventions":605},"NCT02965274","Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablets Under Fed Conditions",[35],"2014-01","2013-11",[16],[592,606],"Warner Chilcott LLC's Sarafem",{"nctId":608,"briefTitle":609,"status":54,"phases":610,"primaryCompletion":602,"completion":602,"start":603,"enrollment":294,"conditions":611,"interventions":612},"NCT02965261","Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablet Under Fasting Conditions",[35],[16],[592,613],"Warner Chilcott LLC Sarafem",{"trials":615,"activeCount":8},[],{"trials":617,"activeCount":8},[],{"trials":619,"activeCount":8},[],{"trials":621,"activeCount":8},[],{"intervention":623,"totalTrials":43,"cells":624},"Risperidone",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":647},{"trials":626,"activeCount":8},[],{"trials":628,"activeCount":8},[629,635],{"nctId":630,"briefTitle":631,"status":54,"phases":632,"conditions":633,"interventions":634},"NCT00939497","Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions",[35],[13],[623],{"nctId":636,"briefTitle":637,"status":54,"phases":638,"conditions":639,"interventions":640},"NCT00939926","Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions",[35],[13],[623],{"trials":642,"activeCount":8},[],{"trials":644,"activeCount":8},[],{"trials":646,"activeCount":8},[],{"trials":648,"activeCount":8},[],{"intervention":650,"totalTrials":43,"cells":651},"Torrent's Alfuzosin Extended Release",{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":668,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":653,"activeCount":8},[],{"trials":655,"activeCount":8},[656,662],{"nctId":657,"briefTitle":658,"status":54,"phases":659,"conditions":660,"interventions":661},"NCT01418599","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions",[35],[13],[650],{"nctId":663,"briefTitle":664,"status":54,"phases":665,"conditions":666,"interventions":667},"NCT01418586","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fasted Conditions",[35],[13],[650],{"trials":669,"activeCount":8},[],{"trials":671,"activeCount":8},[],{"trials":673,"activeCount":8},[],{"trials":675,"activeCount":8},[],{"intervention":677,"totalTrials":43,"cells":678},"Torrent's Isosorbide Mononitrate 120 mg ER",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":695,"PHASE3":697,"PHASE4":699,"NA":701},{"trials":680,"activeCount":8},[],{"trials":682,"activeCount":8},[683,689],{"nctId":684,"briefTitle":685,"status":54,"phases":686,"conditions":687,"interventions":688},"NCT01418534","Bioequivalence Study of Torrent Pharmaceutical Limited's ISMN 120 mg ER Tablets Under Fasting Condition",[35],[13],[677],{"nctId":690,"briefTitle":691,"status":54,"phases":692,"conditions":693,"interventions":694},"NCT01418547","Bioequivalence Study of Torrent Pharmaceutical Limited's Isosorbide Mononitrate 120 mg ER Tablets Under Fed Conditions",[35],[13],[677],{"trials":696,"activeCount":8},[],{"trials":698,"activeCount":8},[],{"trials":700,"activeCount":8},[],{"trials":702,"activeCount":8},[],{"intervention":704,"totalTrials":43,"cells":705},"Zolpidem Tartrate Tablets 10 mg",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":729,"PHASE3":731,"PHASE4":733,"NA":735},{"trials":707,"activeCount":8},[],{"trials":709,"activeCount":8},[710,719],{"nctId":711,"briefTitle":712,"status":54,"phases":713,"primaryCompletion":714,"completion":715,"start":714,"enrollment":716,"conditions":717,"interventions":718},"NCT00939536","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fasted Conditions",[35],"2005-06","2005-07",24,[13],[704],{"nctId":720,"briefTitle":721,"status":54,"phases":722,"primaryCompletion":723,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT00939367","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fed Conditions",[35],"2007-05-02","2007-02-24",50,[13],[704,728],"'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg",{"trials":730,"activeCount":8},[],{"trials":732,"activeCount":8},[],{"trials":734,"activeCount":8},[],{"trials":736,"activeCount":8},[],{"intervention":738,"totalTrials":43,"cells":739},"Torrent's Olmesartan Medoxomil Tablets 40 mg",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":762,"PHASE3":764,"PHASE4":766,"NA":768},{"trials":741,"activeCount":8},[],{"trials":743,"activeCount":8},[744,754],{"nctId":745,"briefTitle":746,"status":54,"phases":747,"primaryCompletion":748,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":752},"NCT03319706","Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions",[35],"2010-09","2010-08",34,[16],[738,753],"Daiichi Sankyo Inc's Benicar Tablets 40 mg",{"nctId":755,"briefTitle":756,"status":54,"phases":757,"primaryCompletion":758,"completion":758,"start":759,"enrollment":750,"conditions":760,"interventions":761},"NCT03318354","Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions",[35],"2010-07","2010-05",[16],[738,753],{"trials":763,"activeCount":8},[],{"trials":765,"activeCount":8},[],{"trials":767,"activeCount":8},[],{"trials":769,"activeCount":8},[],{"intervention":753,"totalTrials":43,"cells":771},{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":784,"PHASE3":786,"PHASE4":788,"NA":790},{"trials":773,"activeCount":8},[],{"trials":775,"activeCount":8},[776,780],{"nctId":745,"briefTitle":746,"status":54,"phases":777,"primaryCompletion":748,"completion":748,"start":749,"enrollment":750,"conditions":778,"interventions":779},[35],[16],[738,753],{"nctId":755,"briefTitle":756,"status":54,"phases":781,"primaryCompletion":758,"completion":758,"start":759,"enrollment":750,"conditions":782,"interventions":783},[35],[16],[738,753],{"trials":785,"activeCount":8},[],{"trials":787,"activeCount":8},[],{"trials":789,"activeCount":8},[],{"trials":791,"activeCount":8},[],{"intervention":793,"totalTrials":43,"cells":794},"Amlodipine besylate",{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":813,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":796,"activeCount":8},[],{"trials":798,"activeCount":8},[799,806],{"nctId":800,"briefTitle":801,"status":54,"phases":802,"conditions":803,"interventions":804},"NCT00932763","Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 22 Fasted, Healthy Adult Subjects",[35],[13],[793,805],"Norvasc",{"nctId":807,"briefTitle":808,"status":54,"phases":809,"conditions":810,"interventions":811},"NCT00932880","Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 18 Fed, Healthy Adult Subjects",[35],[13],[812,805],"Amlodipine Besylate",{"trials":814,"activeCount":8},[],{"trials":816,"activeCount":8},[],{"trials":818,"activeCount":8},[],{"trials":820,"activeCount":8},[],{"intervention":805,"totalTrials":43,"cells":822},{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":835,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":824,"activeCount":8},[],{"trials":826,"activeCount":8},[827,831],{"nctId":800,"briefTitle":801,"status":54,"phases":828,"conditions":829,"interventions":830},[35],[13],[793,805],{"nctId":807,"briefTitle":808,"status":54,"phases":832,"conditions":833,"interventions":834},[35],[13],[812,805],{"trials":836,"activeCount":8},[],{"trials":838,"activeCount":8},[],{"trials":840,"activeCount":8},[],{"trials":842,"activeCount":8},[],{"intervention":844,"totalTrials":43,"cells":845},"Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":847,"activeCount":8},[],{"trials":849,"activeCount":8},[850,857],{"nctId":851,"briefTitle":852,"status":54,"phases":853,"primaryCompletion":854,"conditions":855,"interventions":856},"NCT01800227","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fasting Conditions",[35],"2010-03",[13],[844],{"nctId":858,"briefTitle":859,"status":54,"phases":860,"primaryCompletion":854,"conditions":861,"interventions":862},"NCT01800240","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fed Conditions",[35],[13],[844],{"trials":864,"activeCount":8},[],{"trials":866,"activeCount":8},[],{"trials":868,"activeCount":8},[],{"trials":870,"activeCount":8},[],{"intervention":872,"totalTrials":43,"cells":873},"Torrent's Rosuvastatin Calcium Tablets 40 mg",{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":895,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":875,"activeCount":8},[],{"trials":877,"activeCount":8},[878,888],{"nctId":879,"briefTitle":880,"status":54,"phases":881,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":886},"NCT02962310","Bio Equivalence Study of Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets Under Fasting Condition.",[35],"2009-11","2009-10",48,[16],[872,887],"Crestor 40 mg Tablets of AstraZeneca LP, USA",{"nctId":889,"briefTitle":890,"status":54,"phases":891,"primaryCompletion":541,"completion":541,"start":882,"enrollment":884,"conditions":892,"interventions":893},"NCT02962323","Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions",[35],[16],[872,894],"Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA",{"trials":896,"activeCount":8},[],{"trials":898,"activeCount":8},[],{"trials":900,"activeCount":8},[],{"trials":902,"activeCount":8},[],{"intervention":904,"totalTrials":43,"cells":905},"Torrent's Donepezil Hydrochloride Tablets 10mg",{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":922,"PHASE3":924,"PHASE4":926,"NA":928},{"trials":907,"activeCount":8},[],{"trials":909,"activeCount":8},[910,916],{"nctId":911,"briefTitle":912,"status":54,"phases":913,"conditions":914,"interventions":915},"NCT01419340","Bioequivalence Study of Torrent Pharmaceutical Limited's Donepezil Hydrochloride Tablets Under Fasting Conditions",[35],[13],[904],{"nctId":917,"briefTitle":918,"status":54,"phases":919,"conditions":920,"interventions":921},"NCT01419366","Bioequivalence Study of Torrent Pharmaceutical Limited's Donepezil Hydrochloride Tablets Under Fed Conditions",[35],[13],[904],{"trials":923,"activeCount":8},[],{"trials":925,"activeCount":8},[],{"trials":927,"activeCount":8},[],{"trials":929,"activeCount":8},[],{"intervention":931,"totalTrials":43,"cells":932},"Torrent's Felodipine Extended-Release",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":949,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":934,"activeCount":8},[],{"trials":936,"activeCount":8},[937,943],{"nctId":938,"briefTitle":939,"status":54,"phases":940,"conditions":941,"interventions":942},"NCT01630902","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fed Condition",[35],[13],[931],{"nctId":944,"briefTitle":945,"status":54,"phases":946,"conditions":947,"interventions":948},"NCT01630655","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fasting Condition",[35],[13],[931],{"trials":950,"activeCount":8},[],{"trials":952,"activeCount":8},[],{"trials":954,"activeCount":8},[],{"trials":956,"activeCount":8},[],{"intervention":958,"totalTrials":43,"cells":959},"Torrent's Montelukast Sodium chewable Tablets 5mg",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":961,"activeCount":8},[],{"trials":963,"activeCount":8},[964,972],{"nctId":965,"briefTitle":966,"status":54,"phases":967,"primaryCompletion":968,"conditions":969,"interventions":970},"NCT01931514","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium Chewable 5mg Tablet Under Fed Conditions",[35],"2008-02",[13],[958,971],"Singulair® (Montelukast Sodium) Chewable Tablets 5mg",{"nctId":973,"briefTitle":974,"status":54,"phases":975,"primaryCompletion":968,"conditions":976,"interventions":977},"NCT01931501","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium Chewable Tablets 5mg Under Fasted Conditions",[35],[13],[978,971],"Torrent's Montelukast Sodium Chewable Tablets 5mg",{"trials":980,"activeCount":8},[],{"trials":982,"activeCount":8},[],{"trials":984,"activeCount":8},[],{"trials":986,"activeCount":8},[],{"intervention":971,"totalTrials":43,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":1001,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":990,"activeCount":8},[],{"trials":992,"activeCount":8},[993,997],{"nctId":965,"briefTitle":966,"status":54,"phases":994,"primaryCompletion":968,"conditions":995,"interventions":996},[35],[13],[958,971],{"nctId":973,"briefTitle":974,"status":54,"phases":998,"primaryCompletion":968,"conditions":999,"interventions":1000},[35],[13],[978,971],{"trials":1002,"activeCount":8},[],{"trials":1004,"activeCount":8},[],{"trials":1006,"activeCount":8},[],{"trials":1008,"activeCount":8},[],{"intervention":1010,"totalTrials":43,"cells":1011},"Rabeprazole sodium 20 mg Delayed Release",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1028,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1013,"activeCount":8},[],{"trials":1015,"activeCount":8},[1016,1022],{"nctId":1017,"briefTitle":1018,"status":54,"phases":1019,"primaryCompletion":748,"conditions":1020,"interventions":1021},"NCT01990586","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions",[35],[13],[1010],{"nctId":1023,"briefTitle":1024,"status":54,"phases":1025,"primaryCompletion":748,"conditions":1026,"interventions":1027},"NCT01990378","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fasted Conditions",[35],[13],[1010],{"trials":1029,"activeCount":8},[],{"trials":1031,"activeCount":8},[],{"trials":1033,"activeCount":8},[],{"trials":1035,"activeCount":8},[],{"intervention":1037,"totalTrials":43,"cells":1038},"Sertraline Hydrochloride",{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1056,"PHASE3":1058,"PHASE4":1060,"NA":1062},{"trials":1040,"activeCount":8},[],{"trials":1042,"activeCount":8},[1043,1050],{"nctId":1044,"briefTitle":1045,"status":54,"phases":1046,"conditions":1047,"interventions":1048},"NCT00944242","Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fasting Conditions",[35],[13],[1049,1037],"Sertraline",{"nctId":1051,"briefTitle":1052,"status":54,"phases":1053,"conditions":1054,"interventions":1055},"NCT00946036","Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fed Conditions",[35],[13],[1037],{"trials":1057,"activeCount":8},[],{"trials":1059,"activeCount":8},[],{"trials":1061,"activeCount":8},[],{"trials":1063,"activeCount":8},[],{"intervention":574,"totalTrials":23,"cells":1065},{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1067,"activeCount":8},[],{"trials":1069,"activeCount":8},[1070],{"nctId":566,"briefTitle":567,"status":54,"phases":1071,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":1072,"interventions":1073},[35],[16],[559,574],{"trials":1075,"activeCount":8},[],{"trials":1077,"activeCount":8},[],{"trials":1079,"activeCount":8},[],{"trials":1081,"activeCount":8},[],{"intervention":606,"totalTrials":23,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1092,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1085,"activeCount":8},[],{"trials":1087,"activeCount":8},[1088],{"nctId":599,"briefTitle":600,"status":54,"phases":1089,"primaryCompletion":602,"completion":602,"start":603,"enrollment":294,"conditions":1090,"interventions":1091},[35],[16],[592,606],{"trials":1093,"activeCount":8},[],{"trials":1095,"activeCount":8},[],{"trials":1097,"activeCount":8},[],{"trials":1099,"activeCount":8},[],{"intervention":1101,"totalTrials":23,"cells":1102},"Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide",{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1114,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1104,"activeCount":8},[],{"trials":1106,"activeCount":8},[1107],{"nctId":1108,"briefTitle":1109,"status":54,"phases":1110,"primaryCompletion":569,"completion":569,"start":197,"enrollment":750,"conditions":1111,"interventions":1112},"NCT02962336","Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.",[35],[16],[1101,1113],"Tribenzor Tablets of Daichi Sankyo Inc, USA",{"trials":1115,"activeCount":8},[],{"trials":1117,"activeCount":8},[],{"trials":1119,"activeCount":8},[],{"trials":1121,"activeCount":8},[],{"intervention":1113,"totalTrials":23,"cells":1123},{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1132,"PHASE3":1134,"PHASE4":1136,"NA":1138},{"trials":1125,"activeCount":8},[],{"trials":1127,"activeCount":8},[1128],{"nctId":1108,"briefTitle":1109,"status":54,"phases":1129,"primaryCompletion":569,"completion":569,"start":197,"enrollment":750,"conditions":1130,"interventions":1131},[35],[16],[1101,1113],{"trials":1133,"activeCount":8},[],{"trials":1135,"activeCount":8},[],{"trials":1137,"activeCount":8},[],{"trials":1139,"activeCount":8},[],{"intervention":1141,"totalTrials":23,"cells":1142},"Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1153,"PHASE3":1155,"PHASE4":1157,"NA":1159},{"trials":1144,"activeCount":8},[],{"trials":1146,"activeCount":8},[1147],{"nctId":1148,"briefTitle":1149,"status":54,"phases":1150,"conditions":1151,"interventions":1152},"NCT01418612","Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions",[35],[13],[1141],{"trials":1154,"activeCount":8},[],{"trials":1156,"activeCount":8},[],{"trials":1158,"activeCount":8},[],{"trials":1160,"activeCount":8},[],{"intervention":215,"totalTrials":23,"cells":1162},{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1171,"PHASE3":1173,"PHASE4":1175,"NA":1177},{"trials":1164,"activeCount":8},[],{"trials":1166,"activeCount":8},[1167],{"nctId":210,"briefTitle":211,"status":54,"phases":1168,"primaryCompletion":197,"completion":197,"start":197,"enrollment":198,"conditions":1169,"interventions":1170},[35],[13],[215,187],{"trials":1172,"activeCount":8},[],{"trials":1174,"activeCount":8},[],{"trials":1176,"activeCount":8},[],{"trials":1178,"activeCount":8},[],{"intervention":887,"totalTrials":23,"cells":1180},{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1189,"PHASE3":1191,"PHASE4":1193,"NA":1195},{"trials":1182,"activeCount":8},[],{"trials":1184,"activeCount":8},[1185],{"nctId":879,"briefTitle":880,"status":54,"phases":1186,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":1187,"interventions":1188},[35],[16],[872,887],{"trials":1190,"activeCount":8},[],{"trials":1192,"activeCount":8},[],{"trials":1194,"activeCount":8},[],{"trials":1196,"activeCount":8},[],{"intervention":1198,"totalTrials":23,"cells":1199},"Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide",{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1201,"activeCount":8},[],{"trials":1203,"activeCount":8},[1204],{"nctId":1205,"briefTitle":1206,"status":54,"phases":1207,"primaryCompletion":569,"completion":569,"start":197,"enrollment":750,"conditions":1208,"interventions":1209},"NCT02962258","BE Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab - Fed Conditions",[35],[16],[1198,1210],"Tribenzor of Daichi Sankyo Inc. USA",{"trials":1212,"activeCount":8},[],{"trials":1214,"activeCount":8},[],{"trials":1216,"activeCount":8},[],{"trials":1218,"activeCount":8},[],{"intervention":1210,"totalTrials":23,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1229,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1222,"activeCount":8},[],{"trials":1224,"activeCount":8},[1225],{"nctId":1205,"briefTitle":1206,"status":54,"phases":1226,"primaryCompletion":569,"completion":569,"start":197,"enrollment":750,"conditions":1227,"interventions":1228},[35],[16],[1198,1210],{"trials":1230,"activeCount":8},[],{"trials":1232,"activeCount":8},[],{"trials":1234,"activeCount":8},[],{"trials":1236,"activeCount":8},[],{"intervention":1238,"totalTrials":23,"cells":1239},"Olanzapine Orally Disintegrating Tablets 5mg",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1251,"PHASE3":1253,"PHASE4":1255,"NA":1257},{"trials":1241,"activeCount":8},[],{"trials":1243,"activeCount":8},[1244],{"nctId":1245,"briefTitle":1246,"status":54,"phases":1247,"primaryCompletion":1248,"conditions":1249,"interventions":1250},"NCT01996488","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting Condition",[35],"2009-01",[13],[1238],{"trials":1252,"activeCount":8},[],{"trials":1254,"activeCount":8},[],{"trials":1256,"activeCount":8},[],{"trials":1258,"activeCount":8},[],{"intervention":894,"totalTrials":23,"cells":1260},{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1269,"PHASE3":1271,"PHASE4":1273,"NA":1275},{"trials":1262,"activeCount":8},[],{"trials":1264,"activeCount":8},[1265],{"nctId":889,"briefTitle":890,"status":54,"phases":1266,"primaryCompletion":541,"completion":541,"start":882,"enrollment":884,"conditions":1267,"interventions":1268},[35],[16],[872,894],{"trials":1270,"activeCount":8},[],{"trials":1272,"activeCount":8},[],{"trials":1274,"activeCount":8},[],{"trials":1276,"activeCount":8},[],{"intervention":1278,"totalTrials":23,"cells":1279},"Torrent's Pioglitazone Hydrochloride Tablets 45 mg",{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1291,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1281,"activeCount":8},[],{"trials":1283,"activeCount":8},[1284],{"nctId":1285,"briefTitle":1286,"status":54,"phases":1287,"primaryCompletion":1288,"conditions":1289,"interventions":1290},"NCT01797666","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride Tablets Under Fasting Conditions",[35],"2008-09",[13],[1278],{"trials":1292,"activeCount":8},[],{"trials":1294,"activeCount":8},[],{"trials":1296,"activeCount":8},[],{"trials":1298,"activeCount":8},[],{"intervention":1049,"totalTrials":23,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1309,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1302,"activeCount":8},[],{"trials":1304,"activeCount":8},[1305],{"nctId":1044,"briefTitle":1045,"status":54,"phases":1306,"conditions":1307,"interventions":1308},[35],[13],[1049,1037],{"trials":1310,"activeCount":8},[],{"trials":1312,"activeCount":8},[],{"trials":1314,"activeCount":8},[],{"trials":1316,"activeCount":8},[],{"intervention":613,"totalTrials":23,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1327,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1320,"activeCount":8},[],{"trials":1322,"activeCount":8},[1323],{"nctId":608,"briefTitle":609,"status":54,"phases":1324,"primaryCompletion":602,"completion":602,"start":603,"enrollment":294,"conditions":1325,"interventions":1326},[35],[16],[592,613],{"trials":1328,"activeCount":8},[],{"trials":1330,"activeCount":8},[],{"trials":1332,"activeCount":8},[],{"trials":1334,"activeCount":8},[],{"intervention":1336,"totalTrials":23,"cells":1337},"Venlafaxine Hydrochloride Extended-Release Capsules 150mg",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1347,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1339,"activeCount":8},[],{"trials":1341,"activeCount":8},[1342],{"nctId":1343,"briefTitle":1149,"status":54,"phases":1344,"conditions":1345,"interventions":1346},"NCT01418625",[35],[13],[1336],{"trials":1348,"activeCount":8},[],{"trials":1350,"activeCount":8},[],{"trials":1352,"activeCount":8},[],{"trials":1354,"activeCount":8},[],{"intervention":1356,"totalTrials":23,"cells":1357},"Torrent's Pioglitazone",{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1368,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1359,"activeCount":8},[],{"trials":1361,"activeCount":8},[1362],{"nctId":1363,"briefTitle":1364,"status":54,"phases":1365,"primaryCompletion":1288,"conditions":1366,"interventions":1367},"NCT01798940","Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride Tablets Under Fed Conditions",[35],[13],[1356],{"trials":1369,"activeCount":8},[],{"trials":1371,"activeCount":8},[],{"trials":1373,"activeCount":8},[],{"trials":1375,"activeCount":8},[],{"intervention":728,"totalTrials":23,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1386,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1379,"activeCount":8},[],{"trials":1381,"activeCount":8},[1382],{"nctId":720,"briefTitle":721,"status":54,"phases":1383,"primaryCompletion":723,"completion":723,"start":724,"enrollment":725,"conditions":1384,"interventions":1385},[35],[13],[704,728],{"trials":1387,"activeCount":8},[],{"trials":1389,"activeCount":8},[],{"trials":1391,"activeCount":8},[],{"trials":1393,"activeCount":8},[],{"intervention":1395,"totalTrials":23,"cells":1396},"Olanzapine Orally Disintegrating 5mg",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1407,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1398,"activeCount":8},[],{"trials":1400,"activeCount":8},[1401],{"nctId":1402,"briefTitle":1403,"status":54,"phases":1404,"primaryCompletion":1248,"conditions":1405,"interventions":1406},"NCT01996501","Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fed Condition",[35],[13],[1395],{"trials":1408,"activeCount":8},[],{"trials":1410,"activeCount":8},[],{"trials":1412,"activeCount":8},[],{"trials":1414,"activeCount":8},[],{"intervention":582,"totalTrials":23,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1425,"PHASE3":1427,"PHASE4":1429,"NA":1431},{"trials":1418,"activeCount":8},[],{"trials":1420,"activeCount":8},[1421],{"nctId":576,"briefTitle":577,"status":54,"phases":1422,"primaryCompletion":569,"completion":569,"start":197,"enrollment":579,"conditions":1423,"interventions":1424},[35],[16],[559,582],{"trials":1426,"activeCount":8},[],{"trials":1428,"activeCount":8},[],{"trials":1430,"activeCount":8},[],{"trials":1432,"activeCount":8},[]]